NCT06035380

Brief Summary

Evaluation of the effect of aromatherapy applied to women with vasomotor complaints on menopausal quality of life and vasomotor symptoms.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
66

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Mar 2023

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 30, 2023

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

June 8, 2023

Completed
3 months until next milestone

First Posted

Study publicly available on registry

September 13, 2023

Completed
18 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2023

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2023

Completed
Last Updated

September 13, 2023

Status Verified

September 1, 2023

Enrollment Period

6 months

First QC Date

June 8, 2023

Last Update Submit

September 12, 2023

Conditions

Keywords

Aromatherapy, Vasomotor Symptoms

Outcome Measures

Primary Outcomes (5)

  • VISUAL ANALOGUE SCALE (VAS)

    VAS is used to convert some values that cannot be measured numerically. This scale is a safe, easily applicable test that has proven itself for a very long time and has been accepted in all the world literature. The test has no language and its ease of implementation is an important advantage. It was used in this study to determine how much hot flashes complaints experienced by women affect their lives. It was explained to the women that one end of the scale did not affect their life at all (0), and that it affected their life too much as they approached the other end (10). The women were asked to mark the number on a divided line with numbers from 0 to 10, and how much they thought their hot flashes had affected their lives.

    Baseline, 1 day

  • Introductory Information Form

    women's socio-demographic characteristics , physical characteristics , pregnancy and birth information (pregnancy). number of people living together, spousal support, menstrual pattern, last menstrual period, age of mother's menopause, chronic diseases, smoking and alcohol use, vasomotor complaints, use of CAM and nursing support are included in a total of 27 questions.

    Baseline, 1 day

  • Hot Flashes Scale Specific to Menopause

    The Menopause-Specific Hot Flashes Scale is used to measure the effect of hot flashes on overall quality of life (item 10) and nine specific activities (item 1-item 9). Nine specific activities: work, social activities, leisure activities, sleep, mood, concentration, relationships with others, sexuality, enjoyment of life. How much hot flashes affect the woman's life during the last two weeks is evaluated by numerical rating method from 0 to 10. A value of 0 means "not at all affected" and a value of 10 means "very much affected". The total score is calculated by adding the numerical values of each item.

    Baseline, 1 day, the ninetieth day

  • Menopause-Specific Quality of Life Scale

    It is a 29-item Likert-type scale. The scale consists of four domains: vasomotor, psychosocial, physical and sexual. Vasomotor domain (questions 1-3), Psychosocial domain (questions 4-10), Physical space (questions 11-26), Sexual domain (questions 27-29), Each sub-domain score in the scale is ranked from 1 to 8. 1 point indicates that there is no problem with that. A score of 2 indicates that the problem exists, exists, but is not bothersome at all. Scores between 3 and 8 indicate the severity of the existing problem and its increasing degrees.

    Baseline, 1 day, the ninetieth day

  • Aromatherapy Form

    The usage time and usage amount of the aromatherapy oil will be filled on the aroma therapy form for 12 weeks.

    12 week

Study Arms (3)

rose oil

EXPERIMENTAL

rose oil will be used

Other: rose oil group

mint oil

EXPERIMENTAL

mint oil will be used

Other: mint oil group

plasebo

PLACEBO COMPARATOR

drinking water will be used

Other: placebo group

Interventions

aromatherapy

plasebo

aromatherapy

mint oil

aromatherapy

rose oil

Eligibility Criteria

Sexfemale(Gender-based eligibility)
Gender Eligibility Details* pre menopause * menopause * post menopause
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Being able to speak Turkish,
  • Getting a score above 5 in VAS
  • Not to be allergic to the aromatherapy oils to be applied,
  • Lack of sense of smell,
  • Accepting to work with essential oils to be studied,
  • Not having entered menopause naturally,
  • Not using hormone replacement therapy,
  • Not using complementary alternative therapy,
  • Women who do not have a psychiatric problem,

You may not qualify if:

  • Wanting to leave the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Eastern Mediterranean University

Famagusta, 99628, Cyprus

RECRUITING

Related Publications (3)

  • Mohebitabar S, Shirazi M, Bioos S, Rahimi R, Malekshahi F, Nejatbakhsh F. Therapeutic efficacy of rose oil: A comprehensive review of clinical evidence. Avicenna J Phytomed. 2017 May-Jun;7(3):206-213.

    PMID: 28748167BACKGROUND
  • Johnson A, Roberts L, Elkins G. Complementary and Alternative Medicine for Menopause. J Evid Based Integr Med. 2019 Jan-Dec;24:2515690X19829380. doi: 10.1177/2515690X19829380.

    PMID: 30868921BACKGROUND
  • Short M. Menopause, mood and management. Climacteric. 2003 Aug;6 Suppl 2:33-6.

    PMID: 14669842BACKGROUND

Central Study Contacts

Gülsen Altan, specialist nurse

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Model Details: randomized controlled trial
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
lecturer

Study Record Dates

First Submitted

June 8, 2023

First Posted

September 13, 2023

Study Start

March 30, 2023

Primary Completion

October 1, 2023

Study Completion

December 31, 2023

Last Updated

September 13, 2023

Record last verified: 2023-09

Data Sharing

IPD Sharing
Will not share

Locations